PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23980545-1	2013	The glycosylation of recombinant beta-glucocerebrosidase, and in particular the exposure of mannose residues, has been shown to be a key factor in the success of ERT (enzyme replacement therapy) for the treatment of GD (Gaucher disease).	Mannose	92-99	glucosylceramidase beta	Homo sapiens	33-56	
28207759-3	2017	Supplementing storage cells with lacking enzyme is accomplished via chronic intravenous administration of recombinant GBA containing mannose-terminated N-linked glycans, mediating the selective uptake by macrophages expressing mannose-binding lectin(s).	Mannose	133-140	glucosylceramidase beta	Homo sapiens	118-121	
30822514-0	2019	Production of recombinant human acid beta-glucosidase with high mannose-type N-glycans in rice gnt1 mutant for potential treatment of Gaucher disease.	Mannose	64-71	glucosylceramidase beta	Homo sapiens	32-53	
14605497-3	2003	However, macrophage-targetted enzyme replacement using intravenous mannose-terminated human glucocerebrosidase (imiglucerase, Cerezyme) is highly effective in ameliorating many of the manifestations of Gaucher"s disease and is a treatment in widespread use.	Mannose	67-74	glucosylceramidase beta	Homo sapiens	112-124	
18020553-3	1998	The enzyme, alglucerase, is glucocerebrosidase derived from human placental tissue; its oligosaccharide chain has been modified to expose terminal mannose residues, facilitating uptake in macrophages.	Mannose	147-154	glucosylceramidase beta	Homo sapiens	12-23	
8878985-0	1996	The entrapment of mannose-terminated glucocerebrosidase (Alglucerase) in human carrier erythrocytes.	Mannose	18-25	glucosylceramidase beta	Homo sapiens	57-68	
8486762-1	1993	Mannose-terminated glucocerebrosidase (alglucerase; Ceredase) was designed for enzyme replacement therapy in Gaucher disease to take advantage of mannose receptor-mediated endocytosis by macrophages.	Mannose	0-7	glucosylceramidase beta	Homo sapiens	39-50	
8486762-4	1993	The fact that the binding of alglucerase by macrophages was mediated principally by a receptor distinct from the classical mannose receptor that binds mannose-BSA was confirmed by differential inhibitors, viz., alpha-methyl-glucoside, fucose, and mannose-BSA, and by its independence on Ca2+.	Mannose	123-130	glucosylceramidase beta	Homo sapiens	29-40	
8486762-4	1993	The fact that the binding of alglucerase by macrophages was mediated principally by a receptor distinct from the classical mannose receptor that binds mannose-BSA was confirmed by differential inhibitors, viz., alpha-methyl-glucoside, fucose, and mannose-BSA, and by its independence on Ca2+.	Mannose	151-158	glucosylceramidase beta	Homo sapiens	29-40	
8486762-6	1993	Endothelial cells also manifest mannose-dependent binding and uptake of alglucerase and may therefore account for a large proportion of the infused alglucerase.	Mannose	32-39	glucosylceramidase beta	Homo sapiens	72-83	
8486762-6	1993	Endothelial cells also manifest mannose-dependent binding and uptake of alglucerase and may therefore account for a large proportion of the infused alglucerase.	Mannose	32-39	glucosylceramidase beta	Homo sapiens	148-159	
1379912-2	1992	Alglucerase is a mannose-terminated form of human placental glucocerebrosidase, developed to treat patients with Gaucher"s disease.	Mannose	17-24	glucosylceramidase beta	Homo sapiens	0-11	
21209725-5	2010	After purification, the enzyme is modified to reveal terminal mannose residues which facilitate selective uptake of the protein, imiglucerase (Cerezyme( )), in macrophage-rich tissues.	Mannose	62-69	glucosylceramidase beta	Homo sapiens	129-141	
19255873-4	2009	Plasma chitotriosidase and MIP-1beta decrease upon successful enzyme replacement therapy (ERT) with mannose-terminated recombinant glucocerebrosidase (alglucerase).	Mannose	100-107	glucosylceramidase beta	Homo sapiens	151-162	
15714077-3	2005	Enzyme replacement therapy (ERT) with mannose-terminated glucocerebrosidase (imiglucerase, Cerezyme, Genzyme Corporation, Cambridge, MA) reverses or ameliorates many of the manifestations of type 1 Gaucher disease.	Mannose	38-45	glucosylceramidase beta	Homo sapiens	77-89	
8825806-0	1996	Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues.	Mannose	56-63	glucosylceramidase beta	Homo sapiens	81-102	
8529110-2	1995	Alglucerase is a form of glucocerebrosidase enriched with terminal mannose moieties, so as to "target" the preparation to the high-affinity macrophage receptor in patients with Gaucher disease.	Mannose	67-74	glucosylceramidase beta	Homo sapiens	0-11	
7985893-1	1995	OBJECTIVE: To compare the efficacy of mannose-terminated glucocerbrosidase prepared from natural (alglucerase; Ceredase, Genzyme Corp., Cambridge, Massachusetts) and recombinant (imiglucerase; Cerezyme, Genzyme Corp.) sources in treating type 1 Gaucher disease.	Mannose	38-45	glucosylceramidase beta	Homo sapiens	179-191